ESTRO 2020 Abstract book

S675 ESTRO 2020

Corsini 15 , L. Livi 16 , E. Garibaldi 17 , M. Tartarelli 1 , C.L. Deatoni 18 , A. Baiguini 1 , F. Bertoni 2 , S.M. Magrini 1 1 University and Spedali Civili di Brescia, Radiotherapy Unit, Brescia, Italy ; 2 University of Modena – AOU Policlinico di Modena, Radiation Oncology Department, Modena, Italy ; 3 San Donato Hospital, Radiation Oncology Department, Arezzo, Italy ; 4 ASST, Spedali Civili, Brescia, Italy ; 5 ARNAS Civico Hospital, adiation Oncology Unit, Palermo, Italy ; 6 Ospedale San Jacopo, Department of Radiation Oncology, Pistoia, Italy ; 7 Policlinico Umberto I- Sapienza University of Rome, Radiation Oncology, Roma, Italy ; 8 S. Andrea Hospital- Sapienza University of Rome, Radiation Oncology, Roma, Italy ; 9 IRCCS MultiMedica, IRCCS MultiMedica, Sesto San Giovanni, Italy ; 10 Ospedale Sant’Anna, Department of Radiotherapy, Como, Italy ; 11 Azienda USL Toscana- Centro- Ospedale S. Maria Annunziata, Department of Radiation Oncology, Firenza, Italy ; 12 Fondazione Policlinico Universitario A. Gemelli – UCSC, Radiation Oncology, Roma, Italy ; 13 Istituto Clinico Humanitas- Humanitas Cancer Center, Radiation Oncology, Milano, Italy ; 14 Istituto Nazionale Tumori-IRCCS-G. Pascale Foundation, Radiation Oncology, Napoli, Italy ; 15 AUSL6, Radioterapia, Livorno, Italy ; 16 AUO Careggi, DAI Oncologia, Firenze, Italy ; 17 IRCCS Candiolo, Radiation Oncology, Torino, Italy ; 18 IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milano, Italy Purpose or Objective To describe early results of the analysis of the tolerability of elective pelvic node irradiation (ENI) with or without androgen deprivation therapy (ADT) in patients (pts) with intermediate/high/very high-risk prostate cancer (PC) enrolled in the PRO-EPI study Material and Methods This is a prospective, multicenter, observational cohort study. Data on consecutive pts with intermediate/high/very high-risk PC planned to receive radical or post-operative prostate radiotherapy (RT) with or without ENI and ADT were recorded in a web-based database. Case Report Form (CRF) with demographic, disease and staging information, quality of life (QoL) and symptoms were compiled. Decision making was based on standard practice. Very preliminary QoL data are presented , analyzing both pre-treatment and 1 month (1m) after treatment questioners. Differences were evaluated with T-Test and Anova in relation with the different variables (SPSS®) The data at presentation and the inherent biases of the dataset at this stage of the study are presented in detail in a companion abstract Results From February 2017 to May 2019, 2112 PC pts were registered and 915 enrolled in 44 Italian RT Centers. Features of the series: ENI 41.8%; mean age 73 yrs; familial PC risk 18.8%; baseline hemoglobin levels ≤10 g/dl 26.5%; locally advanced PC 32.9%; nodal involvement 11%; mean PSA 13,7 ng/ml; Gleason Grade Group 1 in 12.3%, 2 in 22.9%, 3 in 23.1%, 4 in 24.4%, 5 in 17.2%; baseline comorbidity index ≥3 (CIRS) in 19.4%; mean severity index 1.32. Mean pre-treatment physical and mental QoL perception (SF-12) were 49.2 and 49.65, respectively. High mean points in physical and mental QoL (SF12) have been registered. The points do not vary a lot between baseline and 1m after RT (PCS p=0,308; MCS p=0,085), although ENI (PCS p=0,023; MCS p=0,927) and ADT (PCS p=0,026; MCS p=0,331) seem to induce slightly worsening of mean physical QoL values . Baseline mean perceived QoL score for urinary function 77.88, bowel function 88.41, sexual issue 21.97 (UCLA-PCI Italian version). Mean UCLA urinary and bowel points slightly worse after the treatment (p=0.000), in particular mean 1m points are

Conclusion This preliminary report demonstrates that SIB to DIL in prostate cancer patients resulted in similar rates of acute toxicity compared with the results in previous studies of 78-Gy definite radiation without DIL boost. The IPSS scores and IPSS-QOL scores significant increased during the treatment; however, at 4 weeks after the treatment, the scores declined to be equivalent to the baseline. Nevertheless, to ensure that this focal dose escalation technique was safe and feasible, further reports with long- term follow up will be conducted to evaluate the late- toxicity profiles. PO-1192 Elective Pelvic Nodes Irradiation in Patients with Prostate Cancer (PRO-EPI Study) M. Buglione 1 , A. Bruni 2 , L. Bardoscia 1 , S. Borghesi 3 , E. Mazzeo 2 , C. Cozzaglio 4 , G. Mortellaro 5 , L. Triggiani 1 , R. Santini 6 , R. Lisi 7 , M. Valeriani 8 , L. Amara 9 , E. Cagna 10 , S. Fondelli 11 , A.M. Alitto 12 , C. Franzese 13 , P. Muto 14 , A.